Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer： implications for clinical practice

Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer （CRPC） has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the pro...

Full description

Saved in:
Bibliographic Details
Published in:Asian journal of andrology 2017-03, Vol.19 (2), p.143-148
Main Authors: Mizokami, Atsushi, Izumi, Kouji, Konaka, Hiroyuki, Kitagawa, Yasuhide, Kadono, Yoshifumi, Narimoto, Kazutaka, Nohara, Takahiro, Bahl, Amit, Namiki, Mikio
Format: Article
Language:English
Subjects:
Androgen Antagonists - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Bone Neoplasms - blood
Bone Neoplasms - secondary
Cancer metastasis
castration-resistant prostate cancer
new hormonal therapy
prostate-specific antigen
Development and progression
Disease Progression
Estramustine - therapeutic use
Flutamide - therapeutic use
Health aspects
Humans
Kallikreins - blood
Male
Neoplasm Metastasis
Observations
Prostate cancer
Prostate specific antigen
Prostate-Specific Antigen - blood
Prostatic Neoplasms, Castration-Resistant - blood
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer （CRPC） has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the progression of prostate cancer using serum prostate-specific antigen （PSA）. However, serum PSA is not always correlated with the clinical status in CRPC. To evaluate the PSA dynamics with greater precision, understanding of the control of PSA and of the mechanisms of development of CRPC is needed. Moreover, it is necessary to use new hormonal therapies with an appropriate timing to optimally improve the prognosis and the QOL of the patients. In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC.
ISSN:1008-682X
1745-7262
DOI:10.4103/1008-682x.179159